5-HT7 receptor antagonists

A compound of formula (I):

• or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein:
• R1 is selected from a C6-10 carbocyclic aromatic residue substituted with 1-3 R1a, and a 5-10 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from N, O and S, substituted with 0-2 R1a;
• R1a is independently selected at each occurrence from halo, —NO2, —CN, —CF3 and —CF2CF3;
• X is selected from —S(O)2—, —S(O)—, —S—;
• R4 is selected from hydrogen and C1-6 alkyl;
• R4a is taken together with R1 to form a 5 or 6-membered fused heterocyclic ring containing 1-2 heteroatoms selected from O and N, substituted with 1 or 2 carbonyl groups;
• Y is C1-3 alkylene;
• A is selected from a 5 or 6 membered saturated, partially saturated or unsaturated ring which contains from 0-1 heteroatoms selected from N, O and S, substituted with 0-3 R5, napthyl substituted with 0-3 R5, and napthyl fused with ring B substituted with 0-3 R5;
• R5 is selected from C1-5 alkyl, halo and —OCH3;
• n is selected from 1, 2, and 3.